A multi-million-pound clinical trial to find out whether existing drugs could be used to treat people with a debilitating ...

Assisi’s tPEMF™ technology aligns with Fear Free’s mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp.

Half Year Report/Half Year ResultsAsklepios Group: Positive development continued in the first half of 2024 - solid basis for further strategic development 29.08.2024 / 10:00 CET/CESTThe issuer is ...

PALO ALTO, CA / ACCESSWIRE / August 29, 2024 / Bioz, Inc., a leader in AI-driven research solutions, is excited to announce a dynamic new collaboration with PCR Biosystems, a rising star in the world ...

COCONUT CREEK, FL / ACCESSWIRE / August 28, 2024 / New Wave Endo-Surgical Corp. announced that it has been named to the 2024 ...

A recent industry technology user survey by Black Book reveals that over half of provider professionals and 80% of payer ...

A team of administrative nurses from Assisted Home Health & Hospice exhibited extraordinary bravery and quick thinking, which ...

Quarterly / Interim Statement/9 Month figuresSCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance  29.08.2024 / 07:00 CET/CESTThe issuer is solely responsible for ...

MINERAL WELLS, TX / ACCESSWIRE / August 28, 2024 / Depression, a debilitating disorder affecting millions worldwide, may soon be treatable with an alarmingly effective, non-invasive brain stimulation ...

Englewood, CO & Franklin, TN, August 28, 2024 -- Mighty Oak Medical, Inc., Medacta USA, Inc., and Medacta International SA, announced today that they have entered into a settlement and license ...

Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical ...